Verve Therapeutics to Participate in Upcoming Investor Conferences

September 22, 2022 6:30 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following upcoming investor conferences:

  • Guggenheim 2022 Nantucket Therapeutics Conference (fireside chat) on Wednesday, September 28, 2022, at 7:30 a.m. ET in Nantucket, Mass.;
  • Jefferies Cell and Genetic Medicine Summit 2022 (fireside chat) on Thursday, September 29, 2022, at 3:00 p.m. ET in NYC;
  • Chardan 6th Annual Genetic Medicine Conference (fireside chat) on Tuesday, October 4, 2022, at 8:00 a.m. ET in NYC;
  • BMO Virtual Biopharma Spotlight Series: Gene Editing & Therapeutics (fireside chat) on Thursday, October 6, 2022, at 9:50 a.m. ET; and,
  • 2022 Truist Securities Genetic Medicine Summit Rare/Non-Rare Disease Panel (panel discussion) on Thursday, October 20, 2022 at 1:15 p.m. ET.

Live webcasts will be available in the investor section of the company's website at and will be archived for 60 days following the presentations.

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs – VERVE-101 and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels. VERVE-101 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) not at goal on oral therapy. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed in homozygous familial hypercholesterolemia (HoFH) and ultimately in patients with ASCVD who have not achieved goal LDL-C with oral therapy and a PCSK9 inhibitor. For more information, please visit

Investor ContactJen RobinsonVerve Therapeutics, Inc.[email protected]

Media ContactAshlea Kosikowski1AB[email protected]

Primary Logo

Source: Verve Therapeutics

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Globe Newswire, Press Releases

Related Entities

Jefferies & Co, Chardan Capital Markets, Guggenheim